Nathan Vastesaeger

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy
    Nathan Vastesaeger
    Merck Sharp and Dohme, Brussels, Belgium Electronic address
    Reumatol Clin 10:204-9. 2014
  2. pmc Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
    Asta Baranauskaite
    Kaunas Medical University Hospital, Kaunas, Lithuania
    Ann Rheum Dis 71:541-8. 2012
  3. pmc Predicting the outcome of ankylosing spondylitis therapy
    Nathan Vastesaeger
    Schering Plough Corporation, Kenilworth, New Jersey, USA
    Ann Rheum Dis 70:973-81. 2011

Detail Information

Publications3

  1. ncbi request reprint ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy
    Nathan Vastesaeger
    Merck Sharp and Dohme, Brussels, Belgium Electronic address
    Reumatol Clin 10:204-9. 2014
    ..To investigate which of the 2 ankylosing spondylitis (AS) disease activity instruments identifies better those patients with characteristics that have been associated with positive response to anti-TNF therapy...
  2. pmc Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
    Asta Baranauskaite
    Kaunas Medical University Hospital, Kaunas, Lithuania
    Ann Rheum Dis 71:541-8. 2012
    ..To compare the efficacy and safety of treatment with infliximab plus methotrexate with methotrexate alone in methotrexate-naive patients with active psoriatic arthritis (PsA)...
  3. pmc Predicting the outcome of ankylosing spondylitis therapy
    Nathan Vastesaeger
    Schering Plough Corporation, Kenilworth, New Jersey, USA
    Ann Rheum Dis 70:973-81. 2011
    ....